Clinical use of Bevacizumab in treating refractory glaucoma • JML Journal of Medicine and Life

2015, Volume 8, Issue 1, pp 8 – 12

Clinical use of Bevacizumab in treating refractory glaucoma

Issues

Special Issues

Authors and Affiliations

Popescu V ^*

Pricopie S ^**

Totir M ^{** ***}

Iancu R ^****

Yasyn S ^**

Alexandrescu C ^**

* *Anatomy Department, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

** **Department of Clinical Ophthalmology, University Emergency Hospital Bucharest, Romania

*** ***Ophthalmology Department, Regina Maria - private health care network, Bucharest, Romania

**** ****Ophthalmology Department, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

Correspondence to:Totir M, MD Department of Clinical Ophthalmology, University Emergency Hospital Bucharest, 169 Splaiul Independenţei Street, Bucharest, Romania Mobile phone: +407 21 142 155, E-mail: madavoicu@gmail.com

Abstract

Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Though other VEGF inhibitors are being approved for the treatment of ophthalmological conditions, bevacizumab found its way into ophthalmology and clinical practice all around the world.

The objective of this review is to present the ophthalmic dosage and administration pathways of bevacizumab in treating refractory glaucoma patients.

Abbreviations: VEGF = vascular endothelial growth factor, FDA = Food and Drug Administration, AMD = age-related macular degeneration

Keywords

bevacizumabglaucomatrabeculectomyvascular endothelial growth factor

Preview

JMedLife-08-8

Download PDF

About this article

PMC ID: 4397528
PubMed ID: 25914729
DOI:

Article Publishing Date (print): Jan-Mar 2015
Available Online:

Journal information

ISSN Printing: 1844-122X
ISSN Online: 1844-3117
Journal Title: Journal of Medicine and Life

Copyright License: Open Access

This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.